Personalizing the androgen deprivation therapy (ADT) conversations for your patients.
The Prolaris test is an advanced molecular diagnostic test that combines tools like the Gleason score and PSA with a personalized tumor score to provide detailed information about the aggressiveness of a patient’s prostate cancer. This test helps determine whether it is safe to forgo treatment or whether treatment is needed, and the appropriate level of treatment needed for the best outcome. Notably, the Prolaris test is the only biomarker test that can quantify the benefits of adding Androgen Deprivation Therapy (ADT) to radiation therapy (RT), or if it can be safely avoided
Hear from radiation oncologist Dr. Fairchild as he discusses why he orders Prolaris on both his favorable and unfavorable intermediate patients.
"For favorable intermediate-risk patients, active surveillance remains an option, though single-modality treatment is often recommended, with rare cases requiring multi-modality treatment. For elderly patients with unfavorable intermediate risk, particularly those with comorbidities, I typically omit hormone therapy based on Prolaris results and the risks associated with ADT."
Dr. Andrew FairchildRadiation Oncologist at Novant Health
Myriad Genetics’ Prolaris Test, the only biomarker test capable of quantifying the benefits of adding androgen deprivation therapy (ADT) to radiation therapy (RT) for localized prostate cancer, has shown promising results in a recent study published by JCO Precision Oncology. The study, presented by Dr. Jonathan Tward at the 2023 American Society of Clinical Oncology (ASCO) Annual Conference, found that patients with a Prolaris clinical cell-cycle risk (CCR) score above the multimodal threshold could reduce their 10-year risk of metastasis by an average of 8.19% by adding ADT to RT, compared to only a 0.86% reduction for those below the threshold.
Given the significant side effects associated with ADT, such as bone and muscle loss, weight gain, and increased cardiovascular risk, the ability of the Prolaris test to accurately predict the benefit of ADT is particularly valuable. According to Myriad Genetics’ chief scientific officer, Dale Muzzey, more than 85% of patients tested with Prolaris have a CCR score below the multimodal threshold, indicating that they may achieve less than a 1% risk reduction by adding ADT to RT. This information allows many patients to forgo ADT and its associated side effects.
“The Prolaris test does in fact, provide a very consistent and double validated model for the multimodal threshold, which helps in a general sense guide who you should routinely consider ADT for or who you should routinely consider omitting it. But at the moment, it’s the only biomarker that provides this highly personal risk estimate of absolute risk reduction so that the individual can really decide, regardless of threshold, whether using or omitting ADT is probably right for them.”
Dr. Jonathan Tward, MD, PhD, FASTRO, Huntsman Cancer Institute at the University of Utah
References: